https://www.peacehealth.org/medical-topics/id/a620053
Tafasitamab-cxix Injection – Health Information Library | PeaceHealth
Tafasitamab-cxix injection is used to treat certain types of non-Hodgkin's lymphoma (types of cancer that begin in a type of white blood cells that normally...
health informationtafasitamabcxixinjectionlibrary
https://www.ajmc.com/view/managing-the-tafasitamab-triplet-safety-profile-adverse-events-and-clinical-implications-from-inmind
Managing the Tafasitamab Triplet: Safety Profile, Adverse Events, and Clinical Implications from...
Oct 17, 2026 - Christina Poh reviewed the inMIND safety data, noting that the addition of tafasitamab to the lenalidomide and rituximab backbone produced a manageable safety...
safety profileadverse eventsmanagingtafasitamabtriplet
https://www.horizonscangeneesmiddelen.nl/geneesmiddelen/tafasitamab-1?versie=versie-2&taalCode=nl
Tafasitamab | Oncology and Hematology | Medicines | Horizonscan geneesmiddelen
Is indicated in combination with lenalidomide followed by monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell...
tafasitamaboncologyhematologymedicinesgeneesmiddelen
https://ematoinfo.it/congresso/eha/2025/linfoma-follicolare-tutti-i-vantaggi-di-tafasitamab-in-aggiunta-a-r2/
Linfoma follicolare, tutti i vantaggi di tafasitamab in aggiunta a R2 - Ematoinfo
Jun 24, 2025 - Che valore hanno i risultati aggiornati dello studio inMIND su tafasitamab + lenalidomide e rituximab (R2) nella prima recidiva del linfoma follicolare?
in aggiuntalinfomafollicolaretuttivantaggi
https://www.medmedia.at/congress-x-press/eha/tafasitamab-r2-neuer-standard-bei-r-r-fl-patientinnen/
EHA 2025: Tafasitamab + R2 neuer Standard bei R/R FL PatientInnen? | congress-x-press
In der Phase 3-inMIND-Studie wurde bei 548 Patient:innen (medianes Alter 64 Jahre) mit rezidiviertem/refraktärem follikulären Lymphom bzw....
x pressehatafasitamabneuerstandard